Lundbeck wins patent case against six generic medicine producers

A legal dispute over the patent rights for depression treatment Trintellix has been resolved in favor of Lundbeck and its partner Takeda, as a US judge has ruled to uphold patent protection on the drug's active ingredient.

Photo: Jens Dresling

Lundbeck has managed to stave off generic medicine producers – for now. The company and its partner, Takeda, have won a legal battle in the US.

The case concerns depression drug Trintellix, which is marketed in the EU as Brintellix. Lundbeck and Takeda started legal proceedings against six generic medicine producers after they submitted approval applications for their copies of Trintellix, which is one of Lundbeck's most important products. The six companies are Alembic, Lupin, Macleouds, Sandoz, Sigmapharm and Zydus.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs